title: Decreased paraoxonase 1, arylesterase enzyme activity, and enhanced oxidative stress in patients with mitral and aortic valve insufficiency.
abstract: BACKGROUND
  Oxidative stress is reportedly associated with several cardiovascular diseases. The antioxidant ability of high density lipoprotein (HDL) is, at least in part, attributable to the pleiotropic serum paraoxonase (PON1). The aim of the study was to investigate the body oxidant/antioxidant balance in patients with mitral regurgitation (MR) and aortic regurgitation (AR) to get new points of view for the underlying oxidative mechanisms.
  
  
  METHODS
  Oxidative stress index (OSI), total oxidant status (TOS), and total antioxidant status (TAS) were examined in addition to the PON1 and arylesterase (ARE) enzyme activities in fifty-six patients and thirty-seven healthy control subjects.
  
  
  RESULTS
  Serum PON1 and ARE enzyme activities were statistically significantly reduced in heart valve disease (HVD) patients (p = 0.0005 and p < 0.0001, respectively), whereas TOS and OSI levels were found to be significantly higher (p = 0.0021 and p < 0.0001, respectively).
  
  
  CONCLUSIONS
  Serum PON1 activity is reduced in patients with HVD, caused by elevated oxidative stress and disturbances of heart valve metabolism. The findings from this novel detailed approach, implicate an inflammatory/oxidative stress process in the pathogenesis of the valve's presentation associated with the HVD. The strength of the significance in differences encourage us to propose that the role of oxidative stress in HVD pathogenesis is very prominent, and oxidative stress markers are potential ancillary tests to evaluate the state of the disease.
authors.affiliation: Central Laboratories of Antalya Education and Research Hospital of Ministry of Health, Antalya, Turkey. necatyilmaz@hotmail.com
authors.forename: Necat
authors.initials: N
authors.lastname: Yilmaz
authors.forename: Nevin
authors.initials: N
authors.lastname: Simsek
authors.forename: Ozgur
authors.initials: O
authors.lastname: Aydin
authors.forename: Emirhan
authors.initials: E
authors.lastname: Yardan
authors.forename: Sakir
authors.initials: S
authors.lastname: Aslan
authors.forename: Esin
authors.initials: E
authors.lastname: Eren
authors.forename: Aysenur
authors.initials: A
authors.lastname: Yegin
authors.forename: Sadik
authors.initials: S
authors.lastname: Buyukbas
mesh_terms: D000368:Aged; D000975:Antioxidants / Q000378:metabolism; D001022:Aortic Valve Insufficiency / Q000097:blood / Q000201:enzymology*; D043303:Aryldialkylphosphatase / Q000097:blood*; D002265:Carboxylic Ester Hydrolases / Q000097:blood*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008944:Mitral Valve Insufficiency / Q000097:blood / Q000201:enzymology*; D018384:Oxidative Stress / Q000502:physiology*; D011446:Prospective Studies; D012372:ROC Curve; D018709:Statistics, Nonparametric
chemical_list: D000975:Antioxidants; D002265:Carboxylic Ester Hydrolases; C019734:arylesterase; D043303:Aryldialkylphosphatase